Algernon Pharmaceuticals CEO Christopher Moreau joined Steve Darling from Proactive to share news the company has applied for a combined Clinical Trial and Ethics Approval application in the UK for a planned Phase 1 clinical human study of AP-188 or DMT in stroke patients.
Moreau telling Proactive the focus of this study is to investigate prolonged intravenous infusion of DMT, for durations that have never been clinically studied. This data, the company hopes, will help with its Phase 2 acute stroke and rehabilitation studies.